住院老年患者药物审查与减处方临床影响的系统综述与荟萃分析
该系统综述与荟萃分析纳入21项随机对照试验、7项非随机干预研究和2项前瞻性队列研究,评估药物审查与减处方干预对住院老年患者的影响。荟萃分析显示再住院率小幅但显著降低8%(HR 0.92;95%CI 0.85-0.99),死亡率无显著影响(HR 0.98;95%CI 0.96-1.00)。30项研究中21项为高偏倚风险。
要点
- 药物审查与减处方使住院老年患者再住院率降低8%(HR 0.92;95%CI 0.85-0.99)。
- 该干预对死亡率无显著影响(HR 0.98;95%CI 0.96-1.00)。
- 30项纳入研究中21项为高偏倚风险,主要源于干预偏离和随机化过程。
核心结论
- 药物审查与减处方与住院老年患者再住院率降低相关,尤其通过减少潜在不适当用药处方实现。
- 在医院环境中整合全面的药物审查与减处方方案可能改善出院后结局并降低整体医疗费用。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Scopus从建库至2024年1月8日的实验性和观察性前瞻性队列研究。
- 共纳入21项随机对照试验、7项非随机干预研究和2项前瞻性队列研究,合计30项研究。
- 14项研究(46.7%)以药物适宜性为主要结局,其余评估临床结局(如住院时间、再住院、急诊就诊、ADR发生率)和/或生活质量。
主要发现
- 荟萃分析显示药物审查与减处方后再住院率降低8%(HR 0.92;95%CI 0.85-0.99),差异有统计学意义。
- 死亡率无显著影响(HR 0.98;95%CI 0.96-1.00)。
- 30项研究中21项为高偏倚风险,8项存在「一些担忧」,1项为低偏倚风险。
临床怎么用
- 对住院老年患者可考虑实施药物审查与减处方方案,以减少潜在不适当用药处方并降低再住院风险。
- 该干预对死亡率无明显获益,临床决策时应结合患者具体情况综合评估。
局限性
- 多数纳入研究(21/30)为高偏倚风险,主要源于干预偏离和随机化过程。
- 仅8项研究存在「一些担忧」,1项为低偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy is a primary risk factor for the prescription of potentially inappropriate medications (PIMs), drug-drug interactions (DDIs), and ultimately, adverse drug reactions (ADRs). Medication review and deprescribing represent effective strategies to simplify therapeutic regimens, minimize risks, and reduce PIM prescriptions. This systematic review and meta-analysis of experimental and observational studies aimed to evaluate the impact of different medication review and deprescribing interventions in hospitalized older patients. METHODS: Experimental and observational prospective cohort studies evaluating the clinical effects of medication review and deprescribing strategies in older hospitalized patients were searched in the bibliographic databases, PubMed, Embase, and Scopus, from inception until January 8, 2024. A narrative synthesis of the results was provided, along with a meta-analysis of dichotomous data (i.e., re-hospitalizations and mortality). RESULTS: Overall, 21 randomized controlled trials, 7 non-randomized interventional studies, and 2 prospective cohort studies were included in the systematic review. Of these, 14 (46.7%) assessed medication appropriateness as the primary outcome, while the remaining evaluated clinical outcomes (e.g., length of hospital stay, hospital readmissions, emergency department visits, and incidence of ADRs) and/or quality of life. The meta-analysis revealed a slight but statistically significant 8% reduction in hospital readmissions (HR: 0.92; 95% CI: 0.85-0.99) following medication review and deprescribing, but no significant impact on mortality (HR: 0.98; 95% CI: 0.96-1.00). Of the 30 included studies, 21 were considered at high risk of bias, mostly due to potential deviations from intended interventions and randomization processes. The remaining nine studies had "some concerns" (eight studies) or were considered at "low" risk of bias (one study). CONCLUSION: Medication review and deprescribing are associated with potential benefits in reducing hospital readmission rates among hospitalized older patients, particularly through the reduction of PIM prescriptions. The integration of thorough medication review and deprescribing protocols in hospital settings may improve post-discharge outcomes and reduce overall healthcare costs.
引用
- Carollo M, Crisafulli S, Vitturi G, et al. Clinical impact of medication review and deprescribing in older inpatients: A systematic review and meta-analysis. J Am Geriatr Soc. 2024. PMID: 38822740. doi:10.1111/jgs.19035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。